Do liberal thresholds for red cell transfusion result in improved quality of life for patients undergoing intensive chemotherapy for acute myeloid leukemia? A randomized crossover feasibility study

Suzy Morton; Mallika Sekhar; Heather Smethurst; Ana Mora; Renate L Hodge; Cara L Hudson; Joseph Parsons; Valerie Hopkins; Simon J Stanworth

doi:10.3324/haematol.2021.279867

Do liberal thresholds for red cell transfusion result in improved quality of life for patients undergoing intensive chemotherapy for acute myeloid leukemia? A randomized crossover feasibility study

Haematologica. 2022 Jun 1;107(6):1474-1478. doi: 10.3324/haematol.2021.279867.

Authors

Suzy Morton¹, Mallika Sekhar², Heather Smethurst³, Ana Mora³, Renate L Hodge⁴, Cara L Hudson⁵, Joseph Parsons⁶, Valerie Hopkins³, Simon J Stanworth⁷

Affiliations

¹ Department of Clinical Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom. B15 2WB; Medical Department, NHS Blood and Transplant, Birmingham, United Kingdom. B15 2SG. suzy.morton@nhsbt.nhs.uk.
² Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom. NW1 2BU; Royal Free London NHS Foundation Trust, Department of Haematology, London, United Kingdom. NW3 2QG.
³ Clinical Trials Unit, NHS Blood and Transplant, Cambridge, United Kingdom. CB2 0PT.
⁴ Clinical Trials Unit, NHS Blood and Transplant, Cambridge, .
⁵ Clinical Trials Unit, NHS Blood and Transplant, Bristol,.
⁶ Clinical Trials Unit, NHS Blood and Transplant, Bristol, United Kingdom. BS34 8RR.
⁷ Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom. OX3 9BQ; Clinical Department, NHS Blood and Transplant, Oxford, United Kingdom. OX3 9BQ; Radcliffe Department of Medicine, University of Oxford, and NIHR Oxford Biomedical Research Centre.

No abstract available

Publication types

Randomized Controlled Trial

MeSH terms

Cross-Over Studies
Erythrocyte Transfusion / adverse effects
Feasibility Studies
Hemoglobins
Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / etiology
Quality of Life*

Substances

Hemoglobins

Grants and funding

Funding: The study was supported by the NHS Blood and Transplant Clinical Trials Unit (H. Thomas, A. Deary, L. Pankhurst). The study was registered (clinicaltrials gov. Identifier: ISRCTN 96390716), received ethics approval (REC number 16/WM/0406) and adopted onto the UK’s National Institute for Health Research (NIHR) Clinical Research Network Portfolio. This manuscript is independent research funded by NHS Blood and Transplant (REF15/86). The views expressed in this publication are those of the author(s) and not necessarily those of NHS Blood and Transplant.